Sign in

    Robert P. Mauch

    President and Chief Executive Officer at Cencora Inc
    Since October 1, 2024
    Age
    58 years
    Education
    Earned a Pharm.D. from Mercer University and a Ph.D. in pharmaceutical science from the University of South Carolina focusing on health economics and outcomes research.
    Tenure
    Joined COR in 2007 and progressed through multiple leadership roles including Senior VP, Group President, EVP, COO, and President before being appointed as President and Chief Executive Officer on October 1, 2024.

    Also at Cencora Inc

    ESC
    Elizabeth S. Campbell
    Executive Vice President and Chief Legal Officer
    JFC
    James F. Cleary
    Executive Vice President and CFO
    SB
    Silvana Battaglia
    Executive Vice President and Chief Human Resources Officer

    About

    Robert P. Mauch is a seasoned healthcare executive who has dedicated over 25 years to the growth and transformation of COR. He began his journey with the company in 2007 when COR acquired Xcenda, and over the years, he has held an array of leadership positions that have shaped his comprehensive understanding of the pharmaceutical and healthcare industries.

    With a strong academic foundation, he earned advanced degrees that have contributed significantly to his strategic approach. His educational achievements include a Pharm.D. from Mercer University and a Ph.D. in pharmaceutical science from the University of South Carolina, where his focus on health economics and outcomes research has informed his leadership style.

    Throughout his tenure, he has played a pivotal role in COR’s evolution, driving initiatives that have positioned the company as a global provider of pharmaceutical-centered healthcare solutions. Now serving as President and Chief Executive Officer since October 1, 2024, his career reflects a continued commitment to delivering strategic value and nurturing innovation across all levels of the organization.

    $COR Performance Under Robert P. Mauch

    Past Roles

    OrganizationRoleDate RangeDetails
    COR Executive Vice President and Chief Operating OfficerOctober 2022 to September 2024 N/A
    COR Group PresidentFebruary 2019 to September 2022 N/A
    COR Group President, Pharmaceutical Distribution & Strategic Global SourcingJune 2017 to February 2019 N/A
    AmerisourceBergen Drug Corporation PresidentFebruary 2015 to June 2017 N/A
    AmerisourceBergen Drug Corporation Senior Vice President and Chief Operating OfficerMarch 2014 to February 2015 N/A
    AmerisourceBergen Drug Corporation Senior Vice President, OperationsApril 2012 to March 2014 N/A
    AmerisourceBergen Drug Corporation Senior Vice President of Sales and MarketingApril 2011 to April 2012 N/A
    AmerisourceBergen Drug Corporation Senior Vice President, Alternate Care Sales and MarketingMay 2010 to April 2011 N/A
    Xcenda, L.L.C. FounderN/A Acquired by Cencora in 2007

    External Roles

    OrganizationRoleDate RangeDetails
    The Professional Society for Health Economics and Outcomes Research Member N/A N/A
    American Society of Managed Care Pharmacy Member N/A N/A
    American Pharmacists Association Member N/A N/A
    Covenant House of Philadelphia Chairman of the Board N/A N/A

    Fixed Compensation

    Data from  FY 2024
    Component NameAmountPayment ScheduleAdditional Details
    Base Salary$1,039,959 Annual (Fiscal 2024)Fixed annual base salary for fiscal 2024
    Employee Deferral Plan Contributions$160,753 Fiscal 2024Contributions made under the Deferred Compensation Plan
    Company Benefit Restoration Contributions$90,101 Fiscal 2024Contributions to Benefit Restoration Accounts under the Deferred Compensation Plan

    Performance Compensation

    Data from  FY 2024

    Performance Share Awards

    Metric NameDetails
    Grant DateNovember 8, 2023
    Grant Date Fair Value [USD]**$3,600,076
    Target Shares18,294 shares
    Threshold Shares9,147 shares (50% of target)
    Maximum Shares42,076 shares (230% of target, including TSR modifier)
    Performance PeriodOctober 1, 2023 to September 30, 2026
    Performance Metrics & Weighting- Compound Annual Adjusted EPS Growth Rate (75% weighting) <br> - Average Annual Adjusted ROIC (25% weighting) <br> - Relative TSR Modifier (+/- 15%, with payout capped at 100% if TSR is negative)
    Vesting ScheduleAwards vest at the end of the three-year performance period, contingent on achieving the performance metrics

    These performance compensation awards are designed to align the interests of executives with long-term company performance. All payouts depend on meeting the specified performance thresholds, targets, and maximum levels as detailed above.